News

News and Resources

June 5, 2025

April 22, 2025

March 13, 2025

March 11, 2025

March 10, 2025

March 5, 2025

January 28, 2025

January 10, 2025

December 18, 2024

November 20, 2024

November 3, 2024

October 29, 2024

October 21, 2024

October 17, 2024

October 16, 2024

October 2, 2024

September 5, 2024

August 13, 2024

July 30, 2024

Get The Latest News and Developments On Our Longevity Journey

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

By subscribing, you are acknowledging your consent to receive Immorta Bio newsletters

19505 Biscayne Blvd, Ste 2350 Aventura, Florida 33180

305 632-2939

info@immortabio.com

News and Resources

Immorta Bio's Anti-Aging Stem Cell Product Shows Superiority in Rheumatoid Arthritis in Preclinical Studies

Immorta Bio Presents SenoVax™ Cancer Senolytic Immunotherapy Preclinical Data at American Association of Immunologists Meeting

Senescent Cell Removal Unleashes NK Cells Shown to Fight Cancer and Viruses in Animal Models

Immorta Bio Presents SenoVax™ Mediated Tumor Remission Data at International Biotechnology Conference

Reduction of Chemotherapy Associated Accelerated Aging by ImmortaSome™ Personalized Exosome Rejuvenation

Immorta Targets Chemo - Associated Accelerated Aging with Exosomes

SenoVax™ First-in-Class Senolytic Product to be Presented at Society for Immunotherapy of Cancer Symposium

The Trick With Senolytics

Immorta Bio to Present New Data on SenoVax™ and StemCell Revivify™ at Biotech Showcase 2025

Immorta Bio Advances Lung Cancer Immunotherapy with Peer-Reviewed Animal Data on Senolytic Vaccine

Nature Publication Supports Senolytic Approach for Cancer Treatment

Immorta CSO Featured in BioFuture 2024 Longevity Panel

Immorta Bio's SenoVax™ Reduces Growth and Stops Metastasis of Aggressive Breast Cancer Using its First-In-Class Immune Stimulatory Therapy

Featured on The Bio Report Podcast - Targeting Senescent Cells

Immorta Bio CEO Featured in Empowered Patient Podcast

Immorta Bio - Featured on Pharmaceutical Executive

Diseases of Aging: Q&A with Dr. Thomas Ichim

SenoVax™ Breakthrough: Cancer Immunotherapy Preserves Immune Function Post-Chemotherapy in Animal Models

Immunotherapy Success Reinforces Immorta's Innovative Cancer Treatment Strategy

Dr. Russel Kaufman, Renowned Medical Innovator and Business Leader, Joins Immorta Bio's Board of Directors

Subscribe to Immorta Bio's Newsletter